Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/96399
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling |
Autor: | Cuenca-López, María D.; Montero, Juan Carlos CSIC ORCID; Morales, Jorge C.; Prat, Aleix; Pandiella, Atanasio CSIC ORCID CVN ; Ocaña, Alberto | Fecha de publicación: | 30-abr-2014 | Editor: | BioMed Central | Citación: | BMC Cancer 14: 302 (2014) | Resumen: | [Background]: The androgen receptor (AR) plays a central role in the oncogenesis of different tumors, as is the case in prostate cancer. In triple negative breast cancer (TNBC) a gene expression classification has described different subgroups including a luminal androgen subtype. The AR can be controlled by several mechanisms like the activation of membrane tyrosine kinases and downstream signaling pathways. However little is known in TNBC about how the AR is modulated by these mechanisms and the potential therapeutic strategists to inhibit its expression. [Methods]: We used human samples to evaluate the expression of AR by western-blot and phospho-proteomic kinase arrays that recognize membrane tyrosine kinase receptors and downstream mediators. Western-blots in human cell lines were carried out to analyze the expression and activation of individual proteins. Drugs against these kinases in different conditions were used to measure the expression of the androgen receptor. PCR experiments were performed to assess changes in the AR gene after therapeutic modulation of these pathways. [Results]: AR is present in a subset of TNBC and its expression correlates with activated membrane receptor kinases-EGFR and PDGFRβ in human samples and cell lines. Inhibition of the PI3K/mTOR pathway in TNBC cell lines decreased notably the expression of the AR. Concomitant administration of the anti-androgen bicalutamide with the EGFR, PDGFRβ and Erk1/2 inhibitors, decreased the amount of AR compared to each agent given alone, and had an additive anti-proliferative effect. Administration of dihydrotestosterone augmented the expression of AR that was not modified by the inhibition of the PI3K/mTOR or Erk1/2 pathways. AR expression was posttranscriptionally regulated by PI3K or Erk1/2 inhibition. [Conclusion]: Our results describe the expression of the AR in TNBC as a druggable target and further suggest the combination of bicalutamide with inhibitors of EGFR, PDGFRβ or Erk1/2 for future development. | Descripción: | This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License. | Versión del editor: | http://dx.doi.org/10.1186/1471-2407-14-302 | URI: | http://hdl.handle.net/10261/96399 | DOI: | 10.1186/1471-2407-14-302 | ISSN: | 1471-2407 |
Aparece en las colecciones: | (IBMCC) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
1471-2407-14-302.xml | 61,66 kB | XML | Visualizar/Abrir | |
1471-2407-14-302-S2.PDF | 551,3 kB | Adobe PDF | Visualizar/Abrir | |
1471-2407-14-302.pdf | 1,82 MB | Adobe PDF | Visualizar/Abrir | |
1471-2407-14-302-S1.PDF | 1,41 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
29
checked on 29-mar-2024
SCOPUSTM
Citations
48
checked on 25-abr-2024
WEB OF SCIENCETM
Citations
47
checked on 27-feb-2024
Page view(s)
345
checked on 30-abr-2024
Download(s)
593
checked on 30-abr-2024